Digital ulcers in scleroderma patients: A retrospective observational study

Angelo De Cata, M. Inglese, F. Molinaro, S. De Cosmo, R. Rubino, M. Bernal, G. Mazzoccoli

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: The guidelines for digital ulcers (DUs) management in systemic sclerosis (SSc) indicate the use of iloprost to induce wound healing and bosentan to prevent the onset of new DU. The aim of our study was to evaluate whether the combination treatment may surmount the effect of the single drug. Methods: We analyzed data regarding 34 patients with SSc and at least one active DU persisting despite 6 months of iloprost therapy, and treated for other 6 months with a combination therapy, i.e. iloprost plus bosentan. Results: Overall, patients initially presented 69 DUs (58 on the fingers and 11 on the legs). At the end of the study 34 (49.3%) DUs were completely healed (responding, R), 18 (26.1%) started the healing process (partially responding, PR), and 17 (24.6%) did not respond (NR) to therapy. No new DU was recorded and the ulcers localized on the legs did not respond to the combination therapy. Finally, data have been analyzed by dividing the patients in two groups according to the fibrosis level on the finger. In the group with mild fibrosis, 83.4% of DUs resulted with showing complete healing while, in the group with severe fibrosis, only 18% of DUs were healed (P = 0.024). Conclusion: The treatment with iloprost plus bosentan is effective in determining healing of DUs in SSc patients with mild digital skin fibrosis. Conversely, the severity of skin fibrosis strongly influences the healing process of DUs. The study confirmed the efficacy of bosentan to prevent onset of new DUs.

Original languageEnglish
Pages (from-to)180-187
Number of pages8
JournalInternational Journal of Immunopathology and Pharmacology
Volume29
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Ulcer
Observational Studies
Retrospective Studies
Iloprost
Fibrosis
Systemic Scleroderma
Fingers
Leg
Therapeutics
Skin
Wound Healing
Guidelines
bosentan

Keywords

  • bosentan
  • digital ulcer
  • iloprost
  • Scleroderma

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

Digital ulcers in scleroderma patients : A retrospective observational study. / De Cata, Angelo; Inglese, M.; Molinaro, F.; De Cosmo, S.; Rubino, R.; Bernal, M.; Mazzoccoli, G.

In: International Journal of Immunopathology and Pharmacology, Vol. 29, No. 2, 2015, p. 180-187.

Research output: Contribution to journalArticle

@article{4e19ab81cf4f4ea593ea877bc1b1e500,
title = "Digital ulcers in scleroderma patients: A retrospective observational study",
abstract = "Background: The guidelines for digital ulcers (DUs) management in systemic sclerosis (SSc) indicate the use of iloprost to induce wound healing and bosentan to prevent the onset of new DU. The aim of our study was to evaluate whether the combination treatment may surmount the effect of the single drug. Methods: We analyzed data regarding 34 patients with SSc and at least one active DU persisting despite 6 months of iloprost therapy, and treated for other 6 months with a combination therapy, i.e. iloprost plus bosentan. Results: Overall, patients initially presented 69 DUs (58 on the fingers and 11 on the legs). At the end of the study 34 (49.3{\%}) DUs were completely healed (responding, R), 18 (26.1{\%}) started the healing process (partially responding, PR), and 17 (24.6{\%}) did not respond (NR) to therapy. No new DU was recorded and the ulcers localized on the legs did not respond to the combination therapy. Finally, data have been analyzed by dividing the patients in two groups according to the fibrosis level on the finger. In the group with mild fibrosis, 83.4{\%} of DUs resulted with showing complete healing while, in the group with severe fibrosis, only 18{\%} of DUs were healed (P = 0.024). Conclusion: The treatment with iloprost plus bosentan is effective in determining healing of DUs in SSc patients with mild digital skin fibrosis. Conversely, the severity of skin fibrosis strongly influences the healing process of DUs. The study confirmed the efficacy of bosentan to prevent onset of new DUs.",
keywords = "bosentan, digital ulcer, iloprost, Scleroderma",
author = "{De Cata}, Angelo and M. Inglese and F. Molinaro and {De Cosmo}, S. and R. Rubino and M. Bernal and G. Mazzoccoli",
year = "2015",
doi = "10.1177/0394632015606846",
language = "English",
volume = "29",
pages = "180--187",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "2",

}

TY - JOUR

T1 - Digital ulcers in scleroderma patients

T2 - A retrospective observational study

AU - De Cata, Angelo

AU - Inglese, M.

AU - Molinaro, F.

AU - De Cosmo, S.

AU - Rubino, R.

AU - Bernal, M.

AU - Mazzoccoli, G.

PY - 2015

Y1 - 2015

N2 - Background: The guidelines for digital ulcers (DUs) management in systemic sclerosis (SSc) indicate the use of iloprost to induce wound healing and bosentan to prevent the onset of new DU. The aim of our study was to evaluate whether the combination treatment may surmount the effect of the single drug. Methods: We analyzed data regarding 34 patients with SSc and at least one active DU persisting despite 6 months of iloprost therapy, and treated for other 6 months with a combination therapy, i.e. iloprost plus bosentan. Results: Overall, patients initially presented 69 DUs (58 on the fingers and 11 on the legs). At the end of the study 34 (49.3%) DUs were completely healed (responding, R), 18 (26.1%) started the healing process (partially responding, PR), and 17 (24.6%) did not respond (NR) to therapy. No new DU was recorded and the ulcers localized on the legs did not respond to the combination therapy. Finally, data have been analyzed by dividing the patients in two groups according to the fibrosis level on the finger. In the group with mild fibrosis, 83.4% of DUs resulted with showing complete healing while, in the group with severe fibrosis, only 18% of DUs were healed (P = 0.024). Conclusion: The treatment with iloprost plus bosentan is effective in determining healing of DUs in SSc patients with mild digital skin fibrosis. Conversely, the severity of skin fibrosis strongly influences the healing process of DUs. The study confirmed the efficacy of bosentan to prevent onset of new DUs.

AB - Background: The guidelines for digital ulcers (DUs) management in systemic sclerosis (SSc) indicate the use of iloprost to induce wound healing and bosentan to prevent the onset of new DU. The aim of our study was to evaluate whether the combination treatment may surmount the effect of the single drug. Methods: We analyzed data regarding 34 patients with SSc and at least one active DU persisting despite 6 months of iloprost therapy, and treated for other 6 months with a combination therapy, i.e. iloprost plus bosentan. Results: Overall, patients initially presented 69 DUs (58 on the fingers and 11 on the legs). At the end of the study 34 (49.3%) DUs were completely healed (responding, R), 18 (26.1%) started the healing process (partially responding, PR), and 17 (24.6%) did not respond (NR) to therapy. No new DU was recorded and the ulcers localized on the legs did not respond to the combination therapy. Finally, data have been analyzed by dividing the patients in two groups according to the fibrosis level on the finger. In the group with mild fibrosis, 83.4% of DUs resulted with showing complete healing while, in the group with severe fibrosis, only 18% of DUs were healed (P = 0.024). Conclusion: The treatment with iloprost plus bosentan is effective in determining healing of DUs in SSc patients with mild digital skin fibrosis. Conversely, the severity of skin fibrosis strongly influences the healing process of DUs. The study confirmed the efficacy of bosentan to prevent onset of new DUs.

KW - bosentan

KW - digital ulcer

KW - iloprost

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=84966701402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966701402&partnerID=8YFLogxK

U2 - 10.1177/0394632015606846

DO - 10.1177/0394632015606846

M3 - Article

AN - SCOPUS:84966701402

VL - 29

SP - 180

EP - 187

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 2

ER -